PiSARRO: p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin/Pegylated Liposomal Doxorubicin Combination Chemotherapy With or Without APR-246
Latest Information Update: 04 Mar 2024
At a glance
- Drugs Eprenetapopt (Primary) ; Carboplatin; Doxorubicin liposomal
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Pharmacokinetics; Proof of concept; Therapeutic Use
- Acronyms PISARRO; PiSARRO
- Sponsors Aprea Therapeutics
- 29 Jul 2019 Status changed from active, no longer recruiting to completed.
- 17 Sep 2018 Planned primary completion date changed from 1 Sep 2018 to 1 Apr 2019.
- 17 Sep 2018 Status changed from recruiting to active, no longer recruiting.